Active Biotech AB (ACTI) — Cash Flow-to-Debt Ratio
Active Biotech AB (ACTI) has a Cash Flow-to-Debt Ratio of -0.73x as of March 2026, meaning its operating cash flow of Skr-8.00 Million could theoretically repay -1% of its total liabilities (Skr11.00 Million) in one year. See how financially flexible is Active Biotech AB to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Active Biotech AB Cash Flow-to-Debt Ratio (2002–2025)
Historical debt coverage capacity for Active Biotech AB across 24 annual periods. For the full cash flow conversion analysis, see Active Biotech AB operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for Active Biotech AB (2002–2025)
Year-by-year debt coverage analysis for Active Biotech AB. Check Active Biotech AB cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.22x | Skr-32.40 Million | Skr14.60 Million | ▲ +38.9% |
| 2024 | -3.63x | Skr-40.40 Million | Skr11.13 Million | ▼ -6.2% |
| 2023 | -3.42x | Skr-45.74 Million | Skr13.38 Million | ▼ -2.8% |
| 2022 | -3.33x | Skr-54.85 Million | Skr16.49 Million | ▲ +27.0% |
| 2021 | -4.56x | Skr-46.17 Million | Skr10.13 Million | ▼ -42.1% |
| 2020 | -3.21x | Skr-32.22 Million | Skr10.04 Million | ▼ -18.0% |
| 2019 | -2.72x | Skr-35.81 Million | Skr13.17 Million | ▼ -1335.0% |
| 2018 | -0.19x | Skr-40.65 Million | Skr214.52 Million | ▲ +7.7% |
| 2017 | -0.21x | Skr-46.45 Million | Skr226.14 Million | ▲ +35.3% |
| 2016 | -0.32x | Skr-73.16 Million | Skr230.32 Million | ▲ +60.8% |
| 2015 | -0.81x | Skr-217.89 Million | Skr268.84 Million | ▲ +3.7% |
| 2014 | -0.84x | Skr-267.09 Million | Skr317.21 Million | ▼ -198.4% |
| 2013 | -0.28x | Skr-102.25 Million | Skr362.40 Million | ▲ +58.1% |
| 2012 | -0.67x | Skr-240.40 Million | Skr356.82 Million | ▼ -411.4% |
| 2011 | -0.13x | Skr-46.97 Million | Skr356.53 Million | ▲ +78.4% |
| 2010 | -0.61x | Skr-196.32 Million | Skr321.34 Million | ▲ +15.8% |
| 2009 | -0.73x | Skr-224.77 Million | Skr309.86 Million | ▼ -40.7% |
| 2008 | -0.52x | Skr-159.46 Million | Skr309.34 Million | ▲ +17.2% |
| 2007 | -0.62x | Skr-186.70 Million | Skr299.97 Million | ▼ -149.9% |
| 2006 | -0.25x | Skr-100.13 Million | Skr402.04 Million | ▲ +49.4% |
| 2005 | -0.49x | Skr-192.51 Million | Skr391.05 Million | ▲ +50.5% |
| 2004 | -0.99x | Skr-149.65 Million | Skr150.59 Million | ▲ +80.8% |
| 2003 | -5.17x | Skr-288.83 Million | Skr55.82 Million | ▼ -54.7% |
| 2002 | -3.34x | Skr-291.71 Million | Skr87.24 Million | — |